The “Pharma-2030” Strategy: Promoting Globalization
03 October 2018
The pharmaceutical market has been actively discussing Pharma-2030 Strategy, which is currently being developed. The opinions and assessments that we hear are often quite different, if not diametrically opposite. The concept of the program must incorporate the interests of all market participants, including manufacturers, who must understand the general trend, the goals and objectives for further development, and the resources they have available for that work. We asked Alexander Kuzin, General Director of NovaMedica Company, to share his opinion of the program as a representative of the manufacturing sector.
03 October 2018
Business gave credence to the government course of developing pharmaceutics. Interview with Vice-Governor of Kaluga Region Vladimir Popov: This year, NovaMedica Company got approval for the conclusion of special investment contract. NovaMedica Company will additionally invest more than 3 billion rubles in modernization of its plant and in technology transfer within the frame of this contract.
Penetrating the European Market
02 October 2018
NovaMedica Innotech is a first-timer at Cphl WorldWide. This is the first opportunity for the company to introduce its products to the European market. NovaMedica Innotech Technology Centre opened its doors in April 2017 in Moscow. It possesses a unique range of innovative Technology platforms for the development and pilot productions of advanced, completive and effective pharmaceuticals.
Researchers provide compelling evidence for multiple STI-detecting device
11 September 2018
Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.
Blood Test Can Identify Patient Response to Prostate Cancer Treatments
17 August 2018
A blood test can help detect whether patients with advanced prostate cancer will respond to a certain treatment, according to a new study. This approach could help better inform the choice of therapy and lead to improved outcomes. In the study, researchers used a liquid biopsy test developed by Epic Sciences to examine circulating tumor cells (CTCs) in blood samples from 142 patients with advanced prostate cancer deciding whether to switch from hormone-targeting therapy to chemotherapy.
Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study
03 August 2018
Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations, or the acute worsening of symptoms such as heavy coughing or shortness of breath, combined with sharp decreases in lung function following irreversible organ damage.
Russia registered a unique drug for the treatment of proctological disorders
29 June 2018
NovaMedica, a Russian pharmaceutical manufacturer and portfolio company of RUSNANO, has registered Fissario®, a unique drug for the treatment of proctological disorders based on a new mechanism of action not used in the products currently available on the market. This is the first drug developed under NovaMedica’s own R&D program. According to the plans, it will become available to patients as early as in 2019.
Alexander Kuzin: You cannot always create everlasting greenhouse conditions for domestic companies
03 May 2018
What is the way of development of the Russian pharma until 2030? What priorities in the development and challenges will be topical for the industry today and tomorrow? These are the questions which occupy minds of all key players of the market, experts and industry regulators. Sure thing! The stage where the Russian pharmaceutical industry is now, can definitely be called transitional – review of results of the state program Pharma-2020 and discussion of principals of the new state program Pharma 2030.
The fifth element of Russian pharma
03 May 2018
Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region.
NovaMedica signs the largest SPIC in pharma industry
13 March 2018
NovaMedica, a Russian pharmaceutical company and investment project of Rusnano, concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga region. The SPIC provides for building from scratch a plant for sterile injectable dosage forms. As part of the project, NovaMedica will invest more than three billion rubles to establish the plant. So far, this is the largest SPIC in the Russian pharmaceutical industry in terms of investments.
05 November 2024
03 November 2024
October 10 – World Mental Health Day
10 October 2024
Siberian State Medical University and Skoltech to start production of bone tissue fillers
22 November 2024
Sechenov University is creating a digital drug reference book
21 November 2024
Skills shortage still holding back pharma's digital transformation: survey
21 November 2024
Trials for Russia’s first CAR-T drug “Utzhefra” have started
20 November 2024